

**AMENDMENTS TO THE SUBSTITUTE SPECIFICATION<sup>1</sup>**

**Page 5, please replace the 6<sup>th</sup> full paragraph (lines 16-23) with the following amended paragraph:**

14. The agent for treating cartilage-related disease according to above-mentioned 1, wherein the substance having an EP2 agonist activity is one or more compounds selected from a compound described in EP860430, a compound described in WO99/33794, a compound described in EP974580, a compound described in WO2003/74483, a compound described in WO95/19964, a compound described in WO98/28264, a compound described in WO99/19300, a compound described in EP0911321, a compound described in US4,132,738 and a compound described in US3,965,143, disclosures of which are incorporated herein by reference.

**Page 6, please replace the first full paragraph (lines 6-11) with the following amended paragraph:**

16. The agent for treating cartilage-related disease according to above-mentioned 1, wherein the substance having an EP3 agonist activity is one or more compounds selected from a compound described in WO98/34916, a compound described in JP-A-8-239356, a compound described in US4,692,464, a compound described in JP-A-61-249951, a compound described in US4,863,961 and a compound described in US3,985,791, disclosures of which are incorporated herein by reference.

---

<sup>1</sup> Filed on March 27, 2008 (both clean and marked-up version)